The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients

Journal of Dermatological Treatment

Volumn 17, Issue 3, 2006, Pages 151-153

  Radmanesh, Mohammed ^a,b   Saedi, Kourosh ^a  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Radmanesh Dermatologic and Laser Research Center   (Iran)

Author keywords

Azathioprine; PUVA; Vitiligo

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; METHOXSALEN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PUVA; RANDOMIZED CONTROLLED TRIAL; SKIN PIGMENTATION; UNSPECIFIED SIDE EFFECT; VITILIGO;

ADMINISTRATION, ORAL; AZATHIOPRINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PUVA THERAPY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VITILIGO;

EID: 33746629839     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630600791442     Document Type: Article

References (11)

1. Naughton GK, Eisinyer M, Bystryn JC. Antibodies to normal human melanocytes in vitiligo. J Exp Med. 1983;158:246-51.
2. Bystryn JC. Theories on the pathogenesis of depigmentation (Immune hypothesis). In: Hann SK, Nordlund JJ, editors. Vitiligo. London: Blackwell Science; 2000. p. 129-34.
3. Naughton GK, Reggiardo MD, Bystryn JC. Correlation between vitiligo autoantibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol. 1986;15(5 Pt 1): 978-81.
4. Harning R, Cui J, Bystryn JC. Relation between the incidence and level on pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol. 1991;97:1078-80.
5. Hann SK, Chen L, Bystryn JC. Systemic steroids suppress anti-melanocyte antibodies in vitiligo. J Cutan Med Surg. 1997;1:193-5.
6. Kao CH, Yu HS. Depletion and repopulation of Langerhans cells in nonsegmental type vitiligo. J Dermatol. 1990;17:287-96.
7. Kozenitzky L, David M, Sredai B, Albeck M, Shohat B. Immunomodulatory effects of AS101 on interleukin-2 production and T-lymphocyte function of lymphocytes treated with psoralens and ultraviolet A. Photodermatol Photoimmunol Photomed. 1992;9:24-8.
8. Gokhale BB, Parakh AP. Cyclophosphamide in vitiligo. Indian J Dermatol. 1983;28:7-10.
9. Csaszar T, Patakfalvi A. Treatment of polyglandular autoimmune syndrome with cyclosporin-A. Acta Med Hung. 1992-93;49(3-4):187-93.
10. Goldstein E, Haberman HF, Menon IA, Pawloski D. Non-psoralen treatment of vitiligo part II: Less commonly used and experimental therapies. Int J Dermatol. 1992;31:314-19.
11. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet. 1994;343:1249-52.